Clinical Study of Recombinant Mycobacterium Tuberculosis ESAT6-CFP10 Allergen

Anhui Zhifei Longcom

Status and phase: Completed; Phase 3

Conditions: Tuberculosis

Treatments: Biological: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm; Biological: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT02623556

LTao-EC III-patient

Details and patient eligibility

About

720 cases TB (Tuberculosis patients) participants、360 cases non-TB participants with lung disease and suspected TB patients who all meet the standard are divided into different groups through a randomized and blind method. Every subject inject intradermally ESAT6-CFP10 and TB-PPD (tuberculin purified protein derivative) in different arms of the same person by blind method. Specific gama-interferon (γ-IFN) detection is needed before the injection.Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe all kind of adverse events.

Full description

Firstly, 720 cases TB (Tuberculosis) participants who meet the standard respectively are divided into different groups through a randomized and blind method.

1. ESAT6-CFP10(10ug/ml) in left arm
2. ESAT6-CFP10(10ug/ml) in right arm. Inject intradermally ESAT6-CFP10 and TB-PPD in different arms of the same participant. For each of participant, the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h. At the same time, we observe the vital signs (breathing, heart rate, blood pressure and temperature), local reactions (rash, pain, itching and skin mucous membrane) and a variety of adverse events.

Secondly, 360 cases non-TB participants with lung disease and suspected TB participants are divided into two different groups and the procedure are as the same as 720 cases TB.

Thirdly,suspected TB participants are put under TB (Tuberculosis patients) or non-TB participants with lung disease by diagnosis when out group.

Finally, we calculate the sensitivity (positive coincidence rate) by TB (Tuberculosis patients), the specificity (negative coincidence rate) by non-TB participants with lung disease, and verify the safety and effectiveness of ESAT6-CFP10(10ug/ml) for the clinical auxiliary diagnosis of tuberculosis.

Enrollment: 1,090 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria of TB (tuberculosis:include pulmonary tuberculosis and extra pulmonary tuberculosis) subjects:

• judge the pulmonary tuberculosis patient according to Health industry standard of the People's Republic of China WS288-2008:Diagnostic Criteria for pulmonary tuberculosis;
• 18 to 65 years old ,no gender limited;
• Consent and signed informed consent forms (ICF);
• Comply with follow-up.

Inclusion Criteria of extra pulmonary tuberculosis subjects:

• Diagnosed extra pulmonary tuberculosis by epidemiology, imaging, clinical symptoms, pathological examination and so on;
• Lesions outside the lungs;
• be in unfinished reinforced phase by chemotherapy;

Exclusion Criteria of TB (tuberculosis) subjects:

• Accompanied by the following severe illness:advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
• Taking part in other clinical or within three months involved in any other clinical;
• Severe allergic constitution:allergic to two or more drugs;
• in pregnancy or lactation;
• in a mental illness;
• Any conditions affect the trial evaluation by investigator's judgement.

Inclusion Criteria of non-TB participants with lung disease:

• A clear lung disease but can exclude pulmonary tuberculosis by clinical symptoms, imaging, laboratory examination.
• 18 to 65 years old, no gender limited;
• Consent and signed informed consent forms (ICF);
• Comply with follow-up.

Exclusion Criteria of non-TB participants with lung disease:

• Accompanied by the following severe illness: advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
• Taking part in other clinical or within three months involved in any other clinical;
• Severe allergic constitution: allergic to two or more drugs;
• in pregnancy or lactation;
• in a mental illness;
• history of tuberculosis;
• Any conditions affect the trial evaluation by investigator's judgement.

Inclusion Criteria of suspected TB participants with lung disease:

• Cases who have pulmonary tuberculosis by clinical symptoms/signs:appear cough、cough with hemoptysis、pectoralgia、dyspnea、fever（low-grade fever at afternoon）,together with night sweats、weak、loss of appetite、weight loss,and so on,or other easily-confused respiratory system disease with TB;
• 18 to 65 years old, no gender limited;
• Consent and signed informed consent forms (ICF);
• Comply with follow-up.

Exclusion Criteria of suspected TB participants with lung disease:

• Accompanied by the following severe illness: advanced cancer, diabetes, copd in acute episodes, acute/progressive liver disease or kidney disease, congestive heart failure, ect;
• Taking part in other clinical or within three months involved in any other clinical;
• Severe allergic constitution: allergic to two or more drugs;
• in pregnancy or lactation;
• in a mental illness;
• history of tuberculosis;
• Any conditions affect the trial evaluation by investigator's judgement.

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

1,090 participants in 2 patient groups

TB subjects

Experimental group

Description:

720 cases TB (Tuberculosis) subjects who meet the standard respectively are divided average into two groups through a randomized and blind method. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm. 360 TB subjects are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. For each of participant,the person in this clinical research, the study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.

Treatment:

Biological: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

Biological: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm

non-TB subjects with lung disease and suspected TB subjects

Experimental group

Description:

360 cases non-TB subjects with lung disease and suspected TB subjects,who meet the standard respectively are divided average into different groups through a randomized and blind method. 180 non-TB subjects with lung disease are injected ESAT6-CFP10(10ug/ml) in left arm and TB-PPD in right arm. 180 non-TB subjects with lung disease are injected ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm. The study uniform is that every subject injects firstly left arm, observe no obvious adverse reaction, then another drug inject in right arm. Measure the induration and (or) redness of longitudinal diameter size and transverse diameter vernier caliper by vernier caliper after injection 24h, 48h and 72h.

Treatment:

Biological: ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm

Biological: ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm